What new treatments for autoimmune diseases are emerging from cancer research?

Researchers are adapting therapies originally designed for cancer to treat autoimmune conditions. These new approaches focus on reprogramming the immune system to stop it from attacking the body's own tissues. Key strategies include engineering specific immune cells and blocking shared inflammatory signals that drive both cancer and autoimmunity.

What the research says

One major area of development involves cell-based therapies. Scientists are using Chimeric Antigen Receptor T-cell (CAR-T) and CAR-engineered regulatory T cell (CAR-Treg) therapies, which were successful in treating cancer, to target autoimmune diseases like Multiple Sclerosis and Type 1 Diabetes ¹. These therapies work by creating T lymphocytes that specifically recognize and stop the immune attack on healthy tissue. However, challenges remain, including high production costs and the need for autologous cell sources ¹.

Another emerging strategy targets tissue-resident memory T cells (Trm). These cells stay in tissues and can cause chronic inflammation in autoimmune diseases, just as they help fight tumors in cancer ². New treatments aim to modulate these cells to reduce tissue damage without compromising the body's ability to fight infections. This approach relies on understanding the specific molecular signals that keep these cells active in the wrong places ².

Researchers are also investigating mitochondrial transfer as a way to reprogram the immune environment. Mitochondria are the energy centers of cells, and they can move between cells to change how immune cells behave ³. By blocking or altering this transfer, scientists hope to reduce the inflammatory tone that fuels autoimmune diseases. This method offers a new way to intervene in the immune system's metabolic state ³.

Finally, drug developers are creating small molecule inhibitors for IRAK4, a protein that drives inflammation in both cancer and autoimmune disorders ⁶. Because IRAK4 is central to the signaling pathways of interleukin-1 and Toll-like receptors, blocking it can calm the immune response. New inhibitors and degraders are being tested to mitigate these diseases by stopping this specific kinase from overactivating ⁶.

What to ask your doctor

• Are there clinical trials for CAR-T or CAR-Treg therapies available for my specific autoimmune condition?
• Could targeting tissue-resident memory T cells be a potential treatment option for my disease?
• Is there research on mitochondrial transfer inhibitors that might help reduce my inflammation?
• Are IRAK4 inhibitors or degraders currently being tested for my type of autoimmune disease?